The company is an innovative drug research and development enterprise with a global perspective based in China, focusing on major diseases such as tumors and metabolic diseases. Based on the concept of solving unmet clinical needs, the company is committed to developing innovative drugs with independent intellectual property rights, created in China, and facing the world, and consistently providing patients with safer, more effective and affordable treatment plans. The company is an innovative drug research and development enterprise with a global perspective based in China, focusing on major diseases such as tumors and metabolic diseases. The company's main products include befotinib mesylate (BPID0316), D-1553, D-0502, D-0120, D-2570, kinase inhibitors, kinase inhibitors, protein inhibitors, etc.
No Data
No Data